A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)

Merck Sharp & Dohme LLC436 enrolled

Overview

This study will evaluate the incidence rate of Candida blood stream infection (candidemia) among people hospitalized in participating medical centers in Brazil, and will assess the antifungal drug susceptibility patterns of Candida clinical isolates. No hypotheses will be tested in the study. Candida blood stream isolates collected from people hospitalized for any reason during the study period will be sent to a core mycology laboratory for antifungal drug susceptibility testing. All people who develop candidemia while hospitalized will be considered participants in the study.

Study Type

OBSERVATIONAL

Enrollment

436

Conditions

Candidemia

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Hospitalized in a participating medical center * Developed candidemia blood stream infection (confirmed by isolation of Candida species from blood culture)

Outcomes

Primary Outcomes

Number of participants with Candidemia per 1000 hospital admissions

A candidemia case was defined as the first isolation of any Candida species from blood within a 30-day period during hospitalization. The incidence of candidemia was calculated as (number of participants / \[number of total people hospitalized during the study period / 1000\])

Time frame: Approximately 1 year

Number of participants with Candidemia per 1000 patient-Days in hospital

A candidemia case was defined as the first isolation of any Candida species from blood within a 30-day period during hospitalization. The incidence of candidemia was calculated as (number of participants / \[number of total patient-days of hospitalization during the study period / 1000\]).

Time frame: Approximately 1 year

Percentage of Specific Candida Isolates Susceptible to Amphotericin B, Fluconazole, Voriconazole, Anidulafungin, and Caspofungin

Candida bloodstream isolates were tested for susceptibility to antifungal drugs using the Clinical and Laboratory Standards Institute (CLSI) microbroth dilution method with final readings recorded after 24 hours. The susceptibility cutoffs for antifungal drugs except amphotericin B were from the CLSI M27-S4 Reference Supplement (December 2012). The susceptibility cutoff for amphotericin B was obtained from the published literature.

Time frame: Approximately 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.